Onlygliptin-M 500 Tablet SR is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The synergistic action of these two agents effectively lowers both fasting and postprandial blood glucose levels. Onlygliptin-M 500 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with metformin is insufficient. The sustained-release formulation allows for once-daily dosing, improving patient compliance. It is important to monitor renal function prior to and during therapy, as metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances and hypoglycemia, especially when used with other antidiabetic agents. This combination therapy should be prescribed under medical supervision with appropriate lifestyle modifications for optimal diabetes management.